- Home
- OCX vs ANTX Comparison
OCX vs ANTX Comparison
Compare OCX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCX
- ANTX
- Stock Information
- Founded
- OCX 2009
- ANTX 2017
- Country
- OCX United States
- ANTX United States
- Employees
- OCX N/A
- ANTX N/A
- Industry
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- OCX Health Care
- ANTX Health Care
- Exchange
- OCX Nasdaq
- ANTX Nasdaq
- Market Cap
- OCX 35.1M
- ANTX 37.6M
- IPO Year
- OCX N/A
- ANTX 2022
- Fundamental
- Price
- OCX $2.08
- ANTX $1.27
- Analyst Decision
- OCX Buy
- ANTX Hold
- Analyst Count
- OCX 3
- ANTX 5
- Target Price
- OCX $4.42
- ANTX $3.50
- AVG Volume (30 Days)
- OCX 69.1K
- ANTX 143.7K
- Earning Date
- OCX 11-12-2024
- ANTX 11-13-2024
- Dividend Yield
- OCX N/A
- ANTX N/A
- EPS Growth
- OCX N/A
- ANTX N/A
- EPS
- OCX N/A
- ANTX N/A
- Revenue
- OCX $709,000.00
- ANTX N/A
- Revenue This Year
- OCX N/A
- ANTX N/A
- Revenue Next Year
- OCX $106.34
- ANTX N/A
- P/E Ratio
- OCX N/A
- ANTX N/A
- Revenue Growth
- OCX N/A
- ANTX N/A
- 52 Week Low
- OCX $1.97
- ANTX $0.87
- 52 Week High
- OCX $3.48
- ANTX $21.40
- Technical
- Relative Strength Index (RSI)
- OCX 37.86
- ANTX 44.51
- Support Level
- OCX $2.05
- ANTX $1.34
- Resistance Level
- OCX $2.24
- ANTX $1.28
- Average True Range (ATR)
- OCX 0.21
- ANTX 0.06
- MACD
- OCX -0.00
- ANTX -0.02
- Stochastic Oscillator
- OCX 15.28
- ANTX 21.74
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.